标题
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
作者
关键词
-
出版物
OncoImmunology
Volume 4, Issue 4, Pages e1008814
出版商
Informa UK Limited
发表日期
2015-05-28
DOI
10.1080/2162402x.2015.1008814
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer and the gut microbiota: An unexpected link
- (2015) Laurence Zitvogel et al. Science Translational Medicine
- Trial Watch: Peptide-based anticancer vaccines
- (2015) Jonathan Pol et al. OncoImmunology
- Classification of current anticancer immunotherapies
- (2015) Lorenzo Galluzzi et al. Oncotarget
- Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients
- (2014) M Konstantinou et al. ACTA DERMATO-VENEREOLOGICA
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Adoptive Immunotherapy for Cancer or Viruses
- (2014) Marcela V. Maus et al. Annual Review of Immunology
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
- (2014) V Chiarion-Sileni et al. BRITISH JOURNAL OF CANCER
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
- (2014) Caroline Jochems et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
- (2014) Y. Saenger et al. CLINICAL CANCER RESEARCH
- Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
- (2014) M. Dai et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Impact of myeloid cells on the efficacy of anticancer chemotherapy
- (2014) Laura Senovilla et al. CURRENT OPINION IN IMMUNOLOGY
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
- (2014) Emma D. Deeks DRUGS
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
- (2014) Andreas Herrmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
- (2014) Vanna Chiarion Sileni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
- (2014) Shravan Madireddi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
- (2014) Sven de Vos et al. Journal of Hematology & Oncology
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Pembrolizumab for treatment of refractory melanoma
- (2014) Sanjeet Bagcchi LANCET ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Protein kinase C-η controls CTLA-4–mediated regulatory T cell function
- (2014) Kok-Fai Kong et al. NATURE IMMUNOLOGY
- Smart therapeutic strategies in immuno-oncology
- (2014) Alexander M. M. Eggermont et al. Nature Reviews Clinical Oncology
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- Curcumin Significantly Enhances Dual PI3K/Akt and mTOR Inhibitor NVP-BEZ235-Induced Apoptosis in Human Renal Carcinoma Caki Cells through Down-Regulation of p53-Dependent Bcl-2 Expression and Inhibition of Mcl-1 Protein Stability
- (2014) Bo Ram Seo et al. PLoS One
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- PD-1 Inhibitor Approved for Melanoma
- (2014) Cancer Discovery
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Finding a needle in a haystack
- (2014) Qunrui Ye et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma
- (2014) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2014) Jonathan Pol et al. OncoImmunology
- Novel insights into the mechanism of action of lenalidomide
- (2014) Michaela Semeraro et al. OncoImmunology
- Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer
- (2014) Aizea Morales-Kastresana et al. OncoImmunology
- Combined OX40 ligation plus CTLA-4 blockade
- (2014) Stefanie N Linch et al. OncoImmunology
- Immune response markers in sentinel nodes may predict melanoma progression
- (2014) Monica Rodolfo et al. OncoImmunology
- A novel combinatorial cancer immunotherapy
- (2014) Toshihiro Nagato et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Trial Watch: Radioimmunotherapy for oncological indications
- (2014) Norma Bloy et al. OncoImmunology
- Immune checkpoints
- (2014) Akhil Chawla et al. OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
- (2014) Huafeng Wei et al. OncoImmunology
- Trial watch
- (2014) Erika Vacchelli et al. OncoImmunology
- The immune landscape of human tumors
- (2014) Gabriela Bindea et al. OncoImmunology
- PD-L1 expression and tumor-infiltrating lymphocytes
- (2014) Kurt A Schalper OncoImmunology
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Trial watch: Dendritic cell-based anticancer therapy
- (2014) Norma Bloy et al. OncoImmunology
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Trial Watch:
- (2014) Jonathan Pol et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2014) Erika Vacchelli et al. OncoImmunology
- Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
- (2013) M Millward et al. BRITISH JOURNAL OF CANCER
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Predictive immunomonitoring — The COST ENTIRE initiative
- (2013) Dusan Popadic et al. CLINICAL IMMUNOLOGY
- The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
- (2013) Amy E Moran et al. CURRENT OPINION IN IMMUNOLOGY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Dendritic-Cell-Based Therapeutic Cancer Vaccines
- (2013) Karolina Palucka et al. IMMUNITY
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
- (2013) Maresa Altomonte et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Immunological checkpoint inhibitors enter adolescence
- (2013) Anna K Nowak LANCET ONCOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Adoptive cell therapy: Honing that killer instinct
- (2013) Courtney Humphries NATURE
- Surgery for NSCLC in the era of personalized medicine
- (2013) Tetsuya Mitsudomi et al. Nature Reviews Clinical Oncology
- Image-guided cancer surgery using near-infrared fluorescence
- (2013) Alexander L. Vahrmeijer et al. Nature Reviews Clinical Oncology
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
- (2013) A Q Butt et al. ONCOGENE
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
- (2013) C. A. Barker et al. Cancer Immunology Research
- Ipilimumab and radiation therapy for melanoma brain metastases
- (2013) Ann W. Silk et al. Cancer Medicine
- Assessing T-cell responses in anticancer immunotherapy
- (2013) David Escors et al. OncoImmunology
- Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
- (2013) Sandra Demaria et al. OncoImmunology
- Immune correlates of melanoma survival in adoptive cell therapy
- (2013) Agnes Fermin Lee et al. OncoImmunology
- Current trends of anticancer immunochemotherapy
- (2013) Erika Vacchelli et al. OncoImmunology
- Prognostic value of the immune microenvironment in lung adenocarcinoma
- (2013) Kyuichi Kadota et al. OncoImmunology
- Trial Watch: Lenalidomide-based immunochemotherapy
- (2013) Michaela Semeraro et al. OncoImmunology
- Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
- (2013) Weiyi Peng et al. OncoImmunology
- Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
- (2013) Haval Shirwan et al. OncoImmunology
- Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I
- (2013) Max Schnurr et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Re-orienting the immune system
- (2013) Evan J. Lipson OncoImmunology
- Development of interferon γ-based immunocytokines targeting renal cancer
- (2013) Peirong Chen et al. OncoImmunology
- Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
- (2013) Jessica Ann Chacon et al. OncoImmunology
- Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
- (2013) Hojabr Kakavand et al. OncoImmunology
- Inhibiting the inhibitors
- (2013) Domenico Mavilio et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Immunogenic cell death in radiation therapy
- (2013) Lorenzo Galluzzi et al. OncoImmunology
- Trial watch
- (2013) Laura Senovilla et al. OncoImmunology
- Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
- (2013) Liza B John et al. OncoImmunology
- Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
- (2013) Zachary A. Cooper et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
- (2013) Sherene Loi OncoImmunology
- Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses
- (2013) Brian Baldo OncoImmunology
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward
- (2012) Anatoli Malyguine et al. Journal of Immunotoxicology
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
- (2012) Antoni Ribas et al. Journal of Translational Medicine
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Abscopal Effect in a Patient with Melanoma
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
- (2012) Rebecca Waitz et al. OncoImmunology
- Trial Watch: Monoclonal antibodies in cancer therapy
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- Trial watch
- (2012) Laura Senovilla et al. OncoImmunology
- Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
- (2012) Roch Houot et al. OncoImmunology
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
- (2012) Adam J. Adler et al. OncoImmunology
- OX40 and CD30 signals in CD4+ T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T-cell memory but not effector function
- (2011) David R. Withers et al. IMMUNOLOGICAL REVIEWS
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
- (2011) Alan Melcher et al. MOLECULAR THERAPY
- Ipilimumab
- (2011) Vernon K. Sondak et al. NATURE REVIEWS DRUG DISCOVERY
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- B regulatory cells and the tumor-promoting actions of TNF- during squamous carcinogenesis
- (2011) T. Schioppa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunity unleashed in melanoma
- (2010) Michael K Erdmann LANCET ONCOLOGY
- Alternatives to surgery after failure of instillation therapy
- (2010) Christian Weiss et al. Nature Reviews Clinical Oncology
- Ipilimumab success in melanoma provides boost for cancer immunotherapy
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
- (2009) Daniel Hirschhorn-Cymerman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Mechanisms maintaining peripheral tolerance
- (2009) Daniel L Mueller NATURE IMMUNOLOGY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells
- (2008) Nathalie T. Joncker et al. IMMUNOLOGICAL REVIEWS
- Negative signaling by inhibitory receptors: the NK cell paradigm
- (2008) Eric O. Long IMMUNOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now